In contrast, VitD effectivity decreased the MDA hepatic concentration and increased hepatic SOD and GSH concentrations in the NAFLD + VitD group compared to the NAFLD group. This evidence concerns the gene SOD1 and metabolic dysfunction-associated steatotic liver disease.